Home >> CGP60474
Related Products
CGP60474 CDKs and PKC inhibitor, potent

Catalog No.A3303
Size Price Stock Qty
10mg
$205.00
In stock
25mg
$390.00
In stock
100mg
$925.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

      

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

CGP60474

CGP60474 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

CGP60474 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties

Cas No. 164658-13-3 SDF Download SDF
Synonyms CGP-60474;CGP 60474
Chemical Name 3-[[4-[2-(3-chloroanilino)pyrimidin-4-yl]pyridin-2-yl]amino]propan-1-ol
Canonical SMILES C1=CC(=CC(=C1)Cl)NC2=NC=CC(=N2)C3=CC(=NC=C3)NCCCO
Formula C18H18ClN5O M.Wt 355.82
Solubility Soluble in DMSO Storage Store at -20°C
Shipping Condition Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Background

CGP60474 is a potent inhibitor of cyclin-dependent kinases (CDKs) with IC50 value of 17 nM for CDK1 [1]. It is also an inhibitor of Protein Kinase C (PKC) [1].
CDKs are a family of protein kinases regulating the cell cycle. PKC plays an important role in signal transductions, cellular proliferation and differentiation [2].
CGP60474 was highly selective for PKC than other serine/threonine and tyrosine kinases and showed competitive kinetics relative to ATP [2].
References:
[1]. Kuo GH, Deangelis A, Emanuel S, et al. Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors. J Med Chem, 2005, 48(14): 4535-4546.
[2]. Stanetty P, Hattinger G, Schnürch M, et al. Novel and efficient access to phenylamino-pyrimidine type protein kinase C inhibitors utilizing a Negishi cross-coupling strategy. J Org Chem, 2005, 70(13): 5215-5220